ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurofibromatosis Type 1 Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-23X8187
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neurofibromatosis Type 1 Market Research Report 2024

Code: QYRE-Auto-23X8187
Report
January 2024
Pages:70
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Merck

Neurofibromatosis Type 1 Market

NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas). 
The global Neurofibromatosis Type 1 market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Neurofibromatosis Type 1 is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neurofibromatosis Type 1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurofibromatosis Type 1.

Report Scope

The Neurofibromatosis Type 1 market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurofibromatosis Type 1 market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurofibromatosis Type 1 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neurofibromatosis Type 1 Market Report

Report Metric Details
Report Name Neurofibromatosis Type 1 Market
Segment by Type
  • 10 mg
  • 25 mg
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Merck
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neurofibromatosis Type 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neurofibromatosis Type 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neurofibromatosis Type 1 Market report?

Ans: The main players in the Neurofibromatosis Type 1 Market are AstraZeneca, Merck

What are the Application segmentation covered in the Neurofibromatosis Type 1 Market report?

Ans: The Applications covered in the Neurofibromatosis Type 1 Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Neurofibromatosis Type 1 Market report?

Ans: The Types covered in the Neurofibromatosis Type 1 Market report are 10 mg, 25 mg

1 Neurofibromatosis Type 1 Market Overview
1.1 Product Overview and Scope of Neurofibromatosis Type 1
1.2 Neurofibromatosis Type 1 Segment by Type
1.2.1 Global Neurofibromatosis Type 1 Market Value Comparison by Type (2024-2030)
1.2.2 10 mg
1.2.3 25 mg
1.3 Neurofibromatosis Type 1 Segment by Application
1.3.1 Global Neurofibromatosis Type 1 Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Neurofibromatosis Type 1 Market Size Estimates and Forecasts
1.4.1 Global Neurofibromatosis Type 1 Revenue 2019-2030
1.4.2 Global Neurofibromatosis Type 1 Sales 2019-2030
1.4.3 Global Neurofibromatosis Type 1 Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Neurofibromatosis Type 1 Market Competition by Manufacturers
2.1 Global Neurofibromatosis Type 1 Sales Market Share by Manufacturers (2019-2024)
2.2 Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Neurofibromatosis Type 1 Average Price by Manufacturers (2019-2024)
2.4 Global Neurofibromatosis Type 1 Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neurofibromatosis Type 1, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurofibromatosis Type 1, Product Type & Application
2.7 Neurofibromatosis Type 1 Market Competitive Situation and Trends
2.7.1 Neurofibromatosis Type 1 Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neurofibromatosis Type 1 Players Market Share by Revenue
2.7.3 Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neurofibromatosis Type 1 Retrospective Market Scenario by Region
3.1 Global Neurofibromatosis Type 1 Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Neurofibromatosis Type 1 Global Neurofibromatosis Type 1 Sales by Region: 2019-2030
3.2.1 Global Neurofibromatosis Type 1 Sales by Region: 2019-2024
3.2.2 Global Neurofibromatosis Type 1 Sales by Region: 2025-2030
3.3 Global Neurofibromatosis Type 1 Global Neurofibromatosis Type 1 Revenue by Region: 2019-2030
3.3.1 Global Neurofibromatosis Type 1 Revenue by Region: 2019-2024
3.3.2 Global Neurofibromatosis Type 1 Revenue by Region: 2025-2030
3.4 North America Neurofibromatosis Type 1 Market Facts & Figures by Country
3.4.1 North America Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.4.3 North America Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neurofibromatosis Type 1 Market Facts & Figures by Country
3.5.1 Europe Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.5.3 Europe Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurofibromatosis Type 1 Market Facts & Figures by Country
3.6.1 Asia Pacific Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.6.3 Asia Pacific Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neurofibromatosis Type 1 Market Facts & Figures by Country
3.7.1 Latin America Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.7.3 Latin America Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurofibromatosis Type 1 Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurofibromatosis Type 1 Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2019-2030)
3.8.3 Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurofibromatosis Type 1 Sales by Type (2019-2030)
4.1.1 Global Neurofibromatosis Type 1 Sales by Type (2019-2024)
4.1.2 Global Neurofibromatosis Type 1 Sales by Type (2025-2030)
4.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Type (2019-2030)
4.2 Global Neurofibromatosis Type 1 Revenue by Type (2019-2030)
4.2.1 Global Neurofibromatosis Type 1 Revenue by Type (2019-2024)
4.2.2 Global Neurofibromatosis Type 1 Revenue by Type (2025-2030)
4.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2030)
4.3 Global Neurofibromatosis Type 1 Price by Type (2019-2030)
5 Segment by Application
5.1 Global Neurofibromatosis Type 1 Sales by Application (2019-2030)
5.1.1 Global Neurofibromatosis Type 1 Sales by Application (2019-2024)
5.1.2 Global Neurofibromatosis Type 1 Sales by Application (2025-2030)
5.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Application (2019-2030)
5.2 Global Neurofibromatosis Type 1 Revenue by Application (2019-2030)
5.2.1 Global Neurofibromatosis Type 1 Revenue by Application (2019-2024)
5.2.2 Global Neurofibromatosis Type 1 Revenue by Application (2025-2030)
5.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2030)
5.3 Global Neurofibromatosis Type 1 Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Neurofibromatosis Type 1 Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Neurofibromatosis Type 1 Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Neurofibromatosis Type 1 Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Neurofibromatosis Type 1 Product Portfolio
6.2.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurofibromatosis Type 1 Industry Chain Analysis
7.2 Neurofibromatosis Type 1 Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurofibromatosis Type 1 Production Mode & Process
7.4 Neurofibromatosis Type 1 Sales and Marketing
7.4.1 Neurofibromatosis Type 1 Sales Channels
7.4.2 Neurofibromatosis Type 1 Distributors
7.5 Neurofibromatosis Type 1 Customers
8 Neurofibromatosis Type 1 Market Dynamics
8.1 Neurofibromatosis Type 1 Industry Trends
8.2 Neurofibromatosis Type 1 Market Drivers
8.3 Neurofibromatosis Type 1 Market Challenges
8.4 Neurofibromatosis Type 1 Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Merck
List of Tables
    Table 1. Global Neurofibromatosis Type 1 Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Neurofibromatosis Type 1 Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Neurofibromatosis Type 1 Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Neurofibromatosis Type 1 Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Neurofibromatosis Type 1 Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Neurofibromatosis Type 1 Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Neurofibromatosis Type 1 Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Neurofibromatosis Type 1 Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Neurofibromatosis Type 1, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Neurofibromatosis Type 1, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Neurofibromatosis Type 1, Product Type & Application
    Table 12. Global Key Manufacturers of Neurofibromatosis Type 1, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Neurofibromatosis Type 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurofibromatosis Type 1 as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Neurofibromatosis Type 1 Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Neurofibromatosis Type 1 Sales by Region (2019-2024) & (K Units)
    Table 18. Global Neurofibromatosis Type 1 Sales Market Share by Region (2019-2024)
    Table 19. Global Neurofibromatosis Type 1 Sales by Region (2025-2030) & (K Units)
    Table 20. Global Neurofibromatosis Type 1 Sales Market Share by Region (2025-2030)
    Table 21. Global Neurofibromatosis Type 1 Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2019-2024)
    Table 23. Global Neurofibromatosis Type 1 Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2025-2030)
    Table 25. North America Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 27. North America Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 28. North America Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Neurofibromatosis Type 1 Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Neurofibromatosis Type 1 Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Neurofibromatosis Type 1 Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Neurofibromatosis Type 1 Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Neurofibromatosis Type 1 Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Neurofibromatosis Type 1 Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Neurofibromatosis Type 1 Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Neurofibromatosis Type 1 Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Neurofibromatosis Type 1 Sales (K Units) by Type (2019-2024)
    Table 51. Global Neurofibromatosis Type 1 Sales (K Units) by Type (2025-2030)
    Table 52. Global Neurofibromatosis Type 1 Sales Market Share by Type (2019-2024)
    Table 53. Global Neurofibromatosis Type 1 Sales Market Share by Type (2025-2030)
    Table 54. Global Neurofibromatosis Type 1 Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Neurofibromatosis Type 1 Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Neurofibromatosis Type 1 Revenue Market Share by Type (2019-2024)
    Table 57. Global Neurofibromatosis Type 1 Revenue Market Share by Type (2025-2030)
    Table 58. Global Neurofibromatosis Type 1 Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Neurofibromatosis Type 1 Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Neurofibromatosis Type 1 Sales (K Units) by Application (2019-2024)
    Table 61. Global Neurofibromatosis Type 1 Sales (K Units) by Application (2025-2030)
    Table 62. Global Neurofibromatosis Type 1 Sales Market Share by Application (2019-2024)
    Table 63. Global Neurofibromatosis Type 1 Sales Market Share by Application (2025-2030)
    Table 64. Global Neurofibromatosis Type 1 Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Neurofibromatosis Type 1 Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Neurofibromatosis Type 1 Revenue Market Share by Application (2019-2024)
    Table 67. Global Neurofibromatosis Type 1 Revenue Market Share by Application (2025-2030)
    Table 68. Global Neurofibromatosis Type 1 Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Neurofibromatosis Type 1 Price (US$/Unit) by Application (2025-2030)
    Table 70. AstraZeneca Corporation Information
    Table 71. AstraZeneca Description and Business Overview
    Table 72. AstraZeneca Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. AstraZeneca Neurofibromatosis Type 1 Product
    Table 74. AstraZeneca Recent Developments/Updates
    Table 75. Merck Corporation Information
    Table 76. Merck Description and Business Overview
    Table 77. Merck Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. Merck Neurofibromatosis Type 1 Product
    Table 79. Merck Recent Developments/Updates
    Table 80. Key Raw Materials Lists
    Table 81. Raw Materials Key Suppliers Lists
    Table 82. Neurofibromatosis Type 1 Distributors List
    Table 83. Neurofibromatosis Type 1 Customers List
    Table 84. Neurofibromatosis Type 1 Market Trends
    Table 85. Neurofibromatosis Type 1 Market Drivers
    Table 86. Neurofibromatosis Type 1 Market Challenges
    Table 87. Neurofibromatosis Type 1 Market Restraints
    Table 88. Research Programs/Design for This Report
    Table 89. Key Data Information from Secondary Sources
    Table 90. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Neurofibromatosis Type 1
    Figure 2. Global Neurofibromatosis Type 1 Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Neurofibromatosis Type 1 Market Share by Type in 2023 & 2030
    Figure 4. 10 mg Product Picture
    Figure 5. 25 mg Product Picture
    Figure 6. Global Neurofibromatosis Type 1 Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Neurofibromatosis Type 1 Market Share by Application in 2023 & 2030
    Figure 8. Hospitals
    Figure 9. Clinics
    Figure 10. Others
    Figure 11. Global Neurofibromatosis Type 1 Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 12. Global Neurofibromatosis Type 1 Market Size (2019-2030) & (US$ Million)
    Figure 13. Global Neurofibromatosis Type 1 Sales (2019-2030) & (K Units)
    Figure 14. Global Neurofibromatosis Type 1 Average Price (US$/Unit) & (2019-2030)
    Figure 15. Neurofibromatosis Type 1 Report Years Considered
    Figure 16. Neurofibromatosis Type 1 Sales Share by Manufacturers in 2023
    Figure 17. Global Neurofibromatosis Type 1 Revenue Share by Manufacturers in 2023
    Figure 18. The Global 5 and 10 Largest Neurofibromatosis Type 1 Players: Market Share by Revenue in 2023
    Figure 19. Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 20. Global Neurofibromatosis Type 1 Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 21. North America Neurofibromatosis Type 1 Sales Market Share by Country (2019-2030)
    Figure 22. North America Neurofibromatosis Type 1 Revenue Market Share by Country (2019-2030)
    Figure 23. U.S. Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 24. Canada Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Europe Neurofibromatosis Type 1 Sales Market Share by Country (2019-2030)
    Figure 26. Europe Neurofibromatosis Type 1 Revenue Market Share by Country (2019-2030)
    Figure 27. Germany Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. France Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. U.K. Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. Italy Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Russia Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Neurofibromatosis Type 1 Sales Market Share by Region (2019-2030)
    Figure 33. Asia Pacific Neurofibromatosis Type 1 Revenue Market Share by Region (2019-2030)
    Figure 34. China Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Japan Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. South Korea Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. India Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. Australia Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Taiwan Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Indonesia Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Thailand Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Malaysia Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Philippines Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Latin America Neurofibromatosis Type 1 Sales Market Share by Country (2019-2030)
    Figure 45. Latin America Neurofibromatosis Type 1 Revenue Market Share by Country (2019-2030)
    Figure 46. Mexico Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Brazil Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Argentina Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Middle East & Africa Neurofibromatosis Type 1 Sales Market Share by Country (2019-2030)
    Figure 50. Middle East & Africa Neurofibromatosis Type 1 Revenue Market Share by Country (2019-2030)
    Figure 51. Turkey Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. Saudi Arabia Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. UAE Neurofibromatosis Type 1 Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. Global Sales Market Share of Neurofibromatosis Type 1 by Type (2019-2030)
    Figure 55. Global Revenue Market Share of Neurofibromatosis Type 1 by Type (2019-2030)
    Figure 56. Global Neurofibromatosis Type 1 Price (US$/Unit) by Type (2019-2030)
    Figure 57. Global Sales Market Share of Neurofibromatosis Type 1 by Application (2019-2030)
    Figure 58. Global Revenue Market Share of Neurofibromatosis Type 1 by Application (2019-2030)
    Figure 59. Global Neurofibromatosis Type 1 Price (US$/Unit) by Application (2019-2030)
    Figure 60. Neurofibromatosis Type 1 Value Chain
    Figure 61. Neurofibromatosis Type 1 Production Process
    Figure 62. Channels of Distribution (Direct Vs Distribution)
    Figure 63. Distributors Profiles
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Cystic Fibrosis (Mucoviscoidosis) Testing Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-24R5886
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Congenital Heart Diseases Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-29D6035
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Gardner Syndrome Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-28H13051
Tue Mar 26 00:00:00 UTC 2024

Add to Cart

Drugs for Alport Syndrome - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-16A13427
Tue Mar 26 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions